{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T01:06:26Z","timestamp":1698973586475},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Versorgungsrealit\u00e4t Trotz klarer Leitlinienempfehlungen werden nur etwa jedem 2. pAVK-Patienten Statine verordnet, Frauen zudem seltener als M\u00e4nnern. Die Rate der eingel\u00f6sten Rezepte liegt drastisch unter der ohnehin schon niedrigen Verschreibungsrate, sodass &lt;\u2153 aller pAVK-Patienten \u00fcberhaupt eine lipidsenkende Therapie einnimmt.<\/jats:p><jats:p>\n            Outcome-Relevanz und erweitertes Therapiespektrum: International besteht Konsens dar\u00fcber, dass jeder pAVK-Patient mit Statinen behandelt werden soll, da diese nicht nur lipidsenkend, sondern auch plaquestabilisierend wirken und hieraus ein prognostischer Nutzen resultiert. Extremit\u00e4tenbezogene Endpunkte, sog. MALE (s.u.), k\u00f6nnen durch Lipidsenkung um 24% im Vergleich zu Placebo reduziert werden. Die Kombination aus niedrigdosiertem hochpotenten Statin mit Ezetimib kann einer hochdosierten Statin-Monotherapie ebenb\u00fcrtig sein und bei besserer Vertr\u00e4glichkeit die Therapieadh\u00e4renz f\u00f6rdern. Im Vergleich zu niedrigpotenten Statinen reduzieren hochpotente Statine die Gesamtmortalit\u00e4t um 36% und haben einen signifikanten Einfluss auf kardiovaskul\u00e4re und extremit\u00e4tenbezogene Endpunkte. Eine Statinintoleranz wird bei bestimmten Risikogruppen h\u00e4ufiger beobachtet, ist insgesamt aber sehr selten. Wirksame Alternativen sind Bempedoins\u00e4ure und PCSK9-Inhibitoren.<\/jats:p><jats:p>\n            Lipoprotein(a) Etwa 20% der Bev\u00f6lkerung haben stark erh\u00f6hte Lp(a)-Werte, die ein \u00fcber das Lipidmanagement hinausgehendes Risikofaktoren-Management erfordern. Eine hohe Lp(a)-Konzentration ist als unabh\u00e4ngiger Risikofaktor f\u00fcr alle Manifestationen der Atherosklerose mit einem pAVK-Progress, erh\u00f6hten Restenoseraten und drastisch erh\u00f6hten Amputationsraten assoziiert. Jeder Erwachsene sollte 1-mal im Leben eine Lp(a)-Bestimmung erhalten.<\/jats:p>","DOI":"10.1055\/a-1956-9891","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:50:23Z","timestamp":1698969023000},"page":"1406-1411","source":"Crossref","is-referenced-by-count":0,"title":["Update \u2013 Lipidsenkende Therapie bei pAVK"],"prefix":"10.1055","volume":"148","author":[{"given":"Katja Sibylle","family":"M\u00fchlberg","sequence":"additional","affiliation":[{"name":"Klinik & Poliklinik f\u00fcr Angiologie, Universit\u00e4tsklinikum Leipzig: Universitatsklinikum Leipzig, Leipzig, GERMANY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1177\/17085381211043952","article-title":"Effects of lipid-lowering therapy on major adverse limb events in patients with peripheral arterial disease: A meta-analysis of randomized clinical trials","volume":"30","author":"W Masson","year":"2022","journal-title":"Vascular"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1358863X20957091","article-title":"Lipid-lowering therapies in peripheral artery disease: A review","volume":"26","author":"N Skeik","year":"2021","journal-title":"Vasc Med"},{"issue":"S 02","key":"ref3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00059-020-04998-w","article-title":"Medikament\u00f6se Sekund\u00e4rpr\u00e4vention bei Patienten mit peripherer arterieller Verschlusskrankheit: Eine sekund\u00e4rdatenbasierte Analyse [Medication-based secondary prevention in patients with peripheral arterial occlusive disease: An analysis based on secondary data]","volume":"46","author":"K Gebauer","year":"2021","journal-title":"Herz"},{"issue":"25","key":"ref4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"e026551","DOI":"10.1161\/JAHA.122.026551","article-title":"Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria","volume":"12","author":"M Aeschbacher-Germann","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"05","key":"ref6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40279-021-01607-6","article-title":"Effectiveness of Fixed-Dose Combination Therapy (Polypill) Versus Exercise to Improve the Blood-Lipid Profile: A Network Meta-analysis","volume":"52","author":"V Mart\u00ednez-Vizca\u00edno","year":"2022","journal-title":"Sports Med"},{"issue":"15","key":"ref7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"SE Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"BK Kim","year":"2022","journal-title":"Lancet"},{"issue":"03","key":"ref9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ejvs.2020.06.006","article-title":"A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial","volume":"60","author":"JV Moxon","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"01","key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers","volume":"81","author":"LJ Laffin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Lowdensity lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"MP Bonaca","year":"2018","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial","volume":"74","author":"JW Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"KK Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1055\/a-1516-2471","article-title":"State of the Art: Therapie mit Statinen [State of the Art: Statin Therapy]","volume":"147","author":"U Laufs","year":"2022","journal-title":"Dtsch Med Wochenschr"},{"issue":"04","key":"ref16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1024\/0301-1526\/a001012","article-title":"Statins and statin intensity in peripheral artery disease","volume":"51","author":"M Sagris","year":"2022","journal-title":"Vasa"},{"issue":"34","key":"ref17","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"I Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"04","key":"ref18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1358863X221091320","article-title":"Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review","volume":"27","author":"W Masson","year":"2022","journal-title":"Vasc Med"},{"issue":"14","key":"ref19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jcin.2022.05.050","article-title":"Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy","volume":"15","author":"Y Tomoi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"ref20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"ML O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1956-9891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:50:47Z","timestamp":1698969047000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1956-9891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":20,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1956-9891","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}